When compared with fibroblastic meningioma, EGFL6 mRNA levels were significantly decreased in all other investigated tumors including glioma (3.84-fold, P<0.01), lung cancer (2.08-fold, P<0.05), hepatocellular carcinoma (2.38-fold, P<0.05), pancreatic carcinoma (2.22-fold, P<0.05), and gastric cancer (3.57-fold, P<0.01), breast cancer (14.29-fold, P<0.001), prostate cancer (8.33-fold, P<0.001), colorectal cancer (14.23-fold, P<0.001), and bladder cancer (10-fold, P<0.001) (Figure 4C). Here, EGFL6 is linked to prostate cancer.